Atsushi Isoda

562 citations
27 papers · 321 indexed · h-index 10
Topics
Multiple Myeloma Research and Treatments (11 papers)Lymphoma Diagnosis and Treatment (8 papers)Peptidase Inhibition and Analysis (6 papers)
Partner nations
JapanNigeria

In The Last Decade

Atsushi Isoda

25 papers receiving 316 citations

Peers

Atsushi Isoda
Comparison fields: 5 of 46
  • Oncology 158
  • Pathology and Forensic Medicine 139
  • Hematology 96
  • Molecular Biology 73
  • Immunology 54
Replace Nahid Nanaji with:
Nahid Nanaji United States
Donna Bucci United States
Monica Onorati Italy
J.P. Farcet France
W.A. van Deijk Netherlands
Nadia Harun Australia
Eugene Nikitin Russia
Arthur I. Radin United States
Yi‐Fang Chang Taiwan
Remi Sumiyoshi Japan
Atsushi Isoda relative to Nahid Nanaji United States Nahid Nanaji's profile →
Citations per field
00.5×
Nahid Nanaji · 1×
Citations per year

Countries citing papers authored by Atsushi Isoda

Since Specialization
Citations

This map shows the geographic impact of Atsushi Isoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsushi Isoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsushi Isoda more than expected).

Fields of papers citing papers by Atsushi Isoda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsushi Isoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsushi Isoda. The network helps show where Atsushi Isoda may publish in the future.

Co-authorship network of co-authors of Atsushi Isoda

This figure shows the co-authorship network connecting the top 25 collaborators of Atsushi Isoda. A scholar is included among the top collaborators of Atsushi Isoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsushi Isoda. Atsushi Isoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 1
3 0
4 1
5 12
6 9
7 5
8 1
9 11
10 4
11 20
12 12
13 92
14 20
15 6
16 14
17 22
18 3
19 8
20 11

About Atsushi Isoda

Atsushi Isoda is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology, having authored 27 papers that have together received 321 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Peptidase Inhibition and Analysis (6 papers). The work is most often cited by research in Hematology (96 citations), Pathology and Forensic Medicine (139 citations) and Oncology (158 citations). Atsushi Isoda has collaborated with scholars based in Japan and Nigeria. Frequent co-authors include Morio Sawamura, Morio Matsumoto, Yuri Miyazawa, Morio Matsumoto, Akio Saito, Kyoichi Kaira, Tomohiro Kinoshita, Mitsune Tanimoto, Kazuhito Yamamoto and Taro Masunari. Their work appears in journals such as Blood, British Journal of Haematology and Cancer Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026